MatthewIMilowskyMD

Genitourinary Oncology

Professor of Medicine, Vice Chief of Research, Section Chief, Genitourinary Oncology, Division of Oncology and Co-Director, Urologic Oncology Program, UNC Lineberger Comprehensive Cancer Center

Join to view full profile

Dr. Milowsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Milowsky's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 919-843-6949

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
State University of New York Downstate Medical Center College of MedicineClass of 1996

Certifications & Licensure

NC State Medical License 2011 - 2026
NY State Medical License 1999 - 2013
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2008 Jul 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer Start of enrollment: 2012 Jul 24
Completed
Not Applicable
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
ACTIVE_NOT_RECRUITING
PHASE2
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Jan 23
Completed
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Terminated
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
ACTIVE_NOT_RECRUITING
PHASE2
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Start of enrollment: 2017 Aug 24
ACTIVE_NOT_RECRUITING
PHASE2
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.
Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs
Bladder Cancer. 2025-02-24
2 citations
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology.
Sandy Figiel, Anthony Bates, David A Braun, Renu Eapen, Markus Eckstein
European Urology. 2025-01-01
2 citations
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, Matthew I Milowsky, Michael Schenker
Journal of Clinical Oncology. 2025-01-01

Lectures

Cost-effectiveness of CHOP in treating DLBCL in Malawi.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Bladder Cancer Survival Better with Nivolumab Than Placebo in New AnalysisFebruary 21st, 2025
Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder CancerFebruary 17th, 2025
Bladder Cancer Biomarkers Promise Improved SurvivalNovember 14th, 2024
Join now to see all